Drug intelligence / Profile preview

boswellia + UC-II

Development stage
Unknown
Lead developer
Doctor's Best
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral
01

Overview

Boswellia + UC-II is a **combination dietary supplement** containing Boswellia serrata extract and undenatured type II collagen (UC-II). Both ingredients are known for supporting joint health and mobility. **Boswellia serrata** contains boswellic acids that inhibit pro-inflammatory enzymes (notably 5-lipoxygenase), thereby reducing leukotriene-mediated inflammation in joints. **UC-II (undenatured type II collagen)** is derived from chicken sternum cartilage and works via *oral tolerance*: it interacts with Peyer’s patches in the gut, inducing the generation of regulatory T cells and subsequent secretion of anti-inflammatory cytokines (e.g., TGF-beta, IL-4, IL-10), modulating immune responses to joint collagen. The combination has demonstrated efficacy in improving mobility and reducing pain and stiffness in humans and dogs with osteoarthritis, with no significant adverse effects reported in trials[1][2][3][6][7][8].

Brand names
Doctor's Best Boswellia with UC-II
Other names
boswellia with UC-IIboswellia serrata + UC-IIboswellia + undenatured type II collagen
02

Targets

CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)PGHS-1 (Prostaglandin G/H Synthase 1)MRP2 (Canalicular multispecific organic anion transporter 1)Cyp (Cyclophilin family)ABCB1 (P-glycoprotein)TOP (DNA topoisomerases)

Beyond the preview

Go deeper on boswellia + UC-II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on boswellia + UC-II.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call